Please login to the form below

Not currently logged in
Email:
Password:

Merck

This page shows the latest Merck news and features for those working in and with pharma, biotech and healthcare.

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’ s consumer health unit. ... Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range.

Latest news

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    Positive data from a first-line NSCLC trial were reported at the American Association of Cancer Research (AACR) meeting this week, but were somewhat eclipsed by data from rival Merck &Co

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    Merck’ s Keytruda meets survival challenge in NSCLC. Data showed that almost 70% of patients on the combo were still alive after 12 months. ... the company’s intelligence unit said it would help push sales of Merck’s drug above $11bn in 2022.

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    Merck’ s Keytruda scores in frontline lung cancer yet again. Drug improved overall survival as a monotherapy, which rival BMS’Opdivo was unable to show. ... That’s not to say Merck’s position in first-line NSCLC is assured - particularly as the

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted

  • Merck KGaA inks deal for Medisafe adherence app Merck KGaA inks deal for Medisafe adherence app

    Merck KGaA inks deal for Medisafe adherence app. The digital programme will be initially rolled out in Brazil, Russia and Mexico. ... It is estimated that approximately 50% of patients do not adhere to long-term therapies, with the problem greater in

More from news
Approximately 351 fully matching, plus 1,015 partially matching documents found.

Latest Intelligence

  • Implementing eHealth innovation Implementing eHealth innovation

    Innovation has driven Merck’s growth and performance to its 350-year celebration in 2018. ... is head of the global business franchise, general medicine and endocrinology at Merck KGaA.

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... Merck &Co grew cardiovascular revenues by 130%, while GSK enjoyed a 214% uplift, mainly due to its PAH treatment Volibris.

  • The bulk of pharma digital spend fails to alter industry’s greenhorn status The bulk of pharma digital spend fails to alter industry’s greenhorn status

    Pfizer, AstraZeneca and Merck fare well on the Cx scores, largely due to the relevance of content provided to HCPs on the go, while Pfizer, Amgen and AZ outscored others on

  • Accelerating innovation Accelerating innovation

    That would be an ideal scenario, ”he said, but as to whether Ipsen has been talking to Merck &Co about its blockbuster immuno-oncology treatment Keytruda (pembrolizumab), he declined to comment.

  • Is AI changing the future of healthcare? Is AI changing the future of healthcare?

    Big pharma is investing in AI; there are now dedicated AI-based drug discovery firms that big players such as GSK, Merck, Sanofi and J&J are turning to, with significant

More from intelligence
Approximately 7 fully matching, plus 110 partially matching documents found.

Latest appointments

More from appointments
Approximately 38 fully matching, plus 132 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics